STOCK TITAN

Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Nuvalent, Inc. (Nasdaq: NUVL) announced that CEO James Porter will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 7:30 a.m. PT in San Francisco. The company, focused on developing targeted therapies for cancer, aims to address the limitations of current treatments. A live webcast of the presentation will be available on the company's website and archived for 30 days. Nuvalent is advancing a pipeline targeting ROS1-positive and ALK-positive lung cancers, HER2 Exon 20 insertion-positive cancers, and other discovery-stage programs.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Jan. 4, 2023 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 7:30 a.m. PT in San Francisco.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), a program in HER2 Exon 20 insertion-positive cancers, and multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301712915.html

SOURCE Nuvalent, Inc.

FAQ

When will Nuvalent present at the J.P. Morgan Healthcare Conference?

Nuvalent will present on January 10, 2023, at 7:30 a.m. PT.

Who is the CEO of Nuvalent and what will he present?

James Porter, CEO of Nuvalent, will present at the 41st Annual J.P. Morgan Healthcare Conference.

How can I watch the Nuvalent presentation online?

The presentation will be available via a live webcast on Nuvalent's website.

What cancer therapies is Nuvalent developing?

Nuvalent is developing targeted therapies primarily for ROS1-positive and ALK-positive non-small cell lung cancer.

What is the date of the J.P. Morgan Healthcare Conference in 2023?

The J.P. Morgan Healthcare Conference is scheduled for January 10, 2023.

Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

NUVL Latest News

NUVL Stock Data

6.27B
64.36M
2.89%
103.24%
7.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE